MedTrace Logo

The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema

NCT03821168 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2019-02-05

No results posted yet for this study

Summary

after advent of RD photoreceptor degeneration Occurred. This process appears as a incredible and progressive event that will not stop till reattachment of RPE and neurosensory retina happened .

Process of degeneration begins from first hours of RD establishment Neuroprotection of photoreceptor following RD is a novel and debatable discussion encountered in recent years .

How to stop this phenomena and neuroprotective agent role in this issue are a new interest of researches.

In the study investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study.

Conditions

  • Refractory Diabetic Macular Edema

Interventions

DRUG

injection of bevacizumab and erythropoietin

injection of bevacizumab and erythropoietin

DRUG

injection of bevacizumab

under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness

Sponsors & Collaborators

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2019-04-01
Completion
2019-10-01

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03821168 on ClinicalTrials.gov